Menu

A Test That Changes Everything

  • In 2022, prostate cancer was the most commonly diagnosed cancer among men in Poland.

  • Approximately 6,000 men die each year due to prostate cancer, and late detection of the disease is one of the leading causes of its high mortality rate.

  • By combining multiple protein markers with a range of genetic markers and clinical data, the Stockholm3 test provides a personalized assessment of prostate cancer risk.

  • It is based on clinical studies involving more than 90,000 men.

  • It has been in clinical practice in Sweden and Norway since 2017.

  • A blood sample is all that is needed.

Early detection is critical for successful treatment.

In Poland, prostate cancer was the most frequently diagnosed cancer among men in 2022. Around 20,000 new cases are diagnosed each year, and this number continues to rise. Unfortunately, 6,000 men die annually from this cancer, with late diagnosis being one of the primary reasons for this high mortality rate. Early detection of prostate cancer can save lives, and modern diagnostic methods help to avoid unnecessary procedures.

What is PSA?

PSA (Prostate-Specific Antigen) is a commonly used marker that aids in detecting prostate cancer. It is produced by both healthy and cancerous cells. This means that an elevated PSA level does not always indicate cancer. It can also be caused by benign prostatic hyperplasia or inflammation of the prostate gland.

Stockholm3 – An Innovative Diagnostic Solution

The Stockholm3 test was developed to improve the accuracy of prostate cancer detection. In addition to PSA, it takes into account other protein and genetic biomarkers, as well as the patient’s clinical data. This makes it more sensitive and specific, meaning that:

  • It more accurately identifies individuals with prostate cancer,

  • It reduces the number of false-positive results,

  • It helps to avoid unnecessary biopsies.

Thanks to Stockholm3, physicians can make an accurate diagnosis and choose the best treatment plan for the patient. Remember, early diagnosis is key to full recovery.

Modern Method with Clear Results

The Stockholm3 test was developed to improve the accuracy of prostate cancer detection. In addition to PSA, it considers other protein and genetic biomarkers, as well as the patient’s clinical data. This makes it more sensitive and specific, meaning that:

  • It more accurately identifies individuals with prostate cancer,

  • It reduces the number of false-positive results,

  • It helps to avoid unnecessary biopsies.

Thanks to Stockholm3, physicians can make an accurate diagnosis and choose the best treatment plan for the patient. Remember, early diagnosis is key to full recovery.

Personalized Recommendations for You

The Stockholm3 test is an innovative diagnostic tool that assesses your individual risk of developing prostate cancer. Using an advanced algorithm, it combines various types of information:

  • Cancer and genetic biomarkers from a blood sample,

  • Clinical data related to your health condition.

All of this to provide a result that is more accurate than standard PSA testing.